Potential of photon-counting detector CT technology for contrast medium reduction in portal venous phase thoracoabdominal CT - Summary - MDSpire

Potential of photon-counting detector CT technology for contrast medium reduction in portal venous phase thoracoabdominal CT

  • By

  • Daniel Popp

  • Martin Siedlecki

  • Lena Friedrich

  • Mark Haerting

  • Christian Scheurig-Muenkler

  • Florian Schwarz

  • Thomas Kroencke

  • Stefanie Bette

  • Josua A. Decker

  • February 12, 2025

  • 0 min

Share

Objective:

To compare image quality (using specific metrics) and contrast enhancement in portal venous phase PCD-CT using different CM volumes and evaluate the potential of low-energy VMI.

Key Findings:
  • PCD-CT demonstrated a higher iodine contrast-to-noise ratio (CNR) compared to EID-CT, with statistical significance.
  • Reduction of CM volume from 120 mL to 100 mL in PCD-CT maintained diagnostic quality.
  • Low-energy VMI at 60 keV improved CNR and diagnostic confidence.
Interpretation:

Photon-counting detector technology allows for effective reduction of contrast medium without compromising image quality, which is crucial for oncologic imaging, enhancing patient safety and addressing environmental concerns.

Limitations:
  • Retrospective design may introduce selection bias and confounding factors.
  • Limited data on portal venous phase PCD-CT compared to arterial phase studies.
Conclusion:

PCD-CT technology holds promise for reducing contrast medium usage in thoracoabdominal CT while maintaining diagnostic efficacy, addressing both patient safety and environmental concerns.

Original Source(s)

Potential of photon-counting detector CT technology for contrast medium reduction in portal venous phase thoracoabdominal CT

  • by Daniel Popp, Martin Siedlecki, Lena Friedrich, Mark Haerting, Christian Scheurig-Muenkler, Florian Schwarz, Thomas Kroencke, Stefanie Bette, Josua A. Decker

  • February 12, 2025

Related Content

Adrenal cortical adenoma-cavernous hemangioma collision tumor: a case report

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

AI Aid Shows Uneven Reporting Gains

Time savings varied by baseline writing time and radiologist in a proof-of-concept study